focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Rockhopper rises as Navitas enters project

Wed, 08th Dec 2021 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Rockhopper Exploration PLC, up 22% at 6.38 pence, 12-month range 4.50p-12.50p. The oil & gas exploration and production company says Navitas Petroleum LP is to enter its Sea Lion oil project in the Falkland Islands. Navitas replaces Harbour Energy PLC as Rockhopper's partner in the project.

----------

Equals Group PLC, up 12% at 70.40p, 12-month range 26.10p-73.00. The fintech payments firm says it has "significantly exceeded" its full-year expectations for both adjusted earnings and revenue. Group revenue for the year to date is GBP40.4 million, up 51% from GBP26.8 million for the same period in 2020. The strong revenue performance means increased gross profit and earnings, and Equals says it has exceeded its own full-year profitability forecasts, but does not provide a figure.

----------

Clinigen Group PLC, up 10% at 901.00p, 12-month range 541.50p-912.00p. Shares hit 12-month high after the pharmaceuticals and services provider agrees to be taken private by European investment firm Triton Funds in a GBP1.2 billion deal. Under the terms, Clinigen shareholders will receive 883p a share in cash. This is a 41% premium to the ex-dividend closing share price on December 1, which was the last business day before takeover talks were first announced. Clinigen shareholders will also be entitled to receive the previously declared final dividend of 5.46p a share.

----------

AIM - LOSERS

----------

Byotrol PLC, down 16% at 4.22p, 12-month range 4.00p-7.70p. Shares in the antimicrobial technologies company hit fresh 12-month low after profit warning and says its first half performance was below expectations. For six months to September 30, swings to pretax loss of GBP141,000 from GBP1.0 million profit year before. "Whilst we expect to be both profitable and cash generative in the second half of the year, with these uncertainties it is difficult to predict the quantum at this juncture. At present we are expecting IP sales to offset the majority of the anticipated shortfall in profit on product sale, but projecting the timing of IP sales is even more uncertain, so we feel it prudent to now reduce market guidance for the current financial year," it says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
14 Jul 2020 09:07

Clinigen FY revenues continue to rise, profit growth slowed by Covid-19

(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug.

Read more
13 Jul 2020 16:29

Clinigen gets orphan drug designation for 'aldesleukin' in the US

(Sharecast News) - Pharmaceutical services company Clinigen Group announced on Monday that the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted orphan drug designation for 'aldesleukin', in the treatment of amyotrophic lateral sclerosis (ALS).

Read more
13 Jul 2020 13:48

Monday broker round-up

(Sharecast News) - Kingfisher: RBC Capital Markets reiterates outperform with a target price of 275.0p

Read more
13 Jul 2020 08:41

Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin

Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin

Read more
14 Jun 2020 19:22

Sunday newspaper round-up: Two meters, Rolls Royce, Clinigen

(Sharecast News) - Senior scientists have reported flaws in an influential World Health Organization-commissioned study into the risks of coronavirus infection and say it should not be used as evidence for relaxing the UK's 2-metre physical distancing rule. Critics of the distancing advice, which states that people should keep at least 2 metres apart, believe it is too cautious. They seized on the research commissioned by the WHO, which suggested a reduction from 2 metres to 1 would raise infection risk only marginally, from 1.3% to 2.6%. - Guardian

Read more
28 May 2020 13:34

Thursday broker round-up

(Sharecast News) - Provident Financial: RBC Capital Markets reiterates sector performer with a target price of 195p.

Read more
28 May 2020 09:37

UK BROKER RATINGS SUMMARY: Jefferies Initiates Greggs, Games Workshop

UK BROKER RATINGS SUMMARY: Jefferies Initiates Greggs, Games Workshop

Read more
26 May 2020 17:50

Clinigen Chair Leaves Audit Committee After Shareholder Engagement

Clinigen Chair Leaves Audit Committee After Shareholder Engagement

Read more
12 May 2020 10:37

McCarthy & Stone CFO Rowan Baker Defects To Laing O'Rourke

McCarthy & Stone CFO Rowan Baker Defects To Laing O'Rourke

Read more
16 Apr 2020 12:00

Clinigen Says Annual Trading In Line; Signs Erwinase License Agreement

Clinigen Says Annual Trading In Line; Signs Erwinase License Agreement

Read more
24 Mar 2020 16:00

DIRECTOR DEALINGS SUMMARY: Pearson And IHG Chairs Buy Amid Virus Pain

DIRECTOR DEALINGS SUMMARY: Pearson And IHG Chairs Buy Amid Virus Pain

Read more
20 Mar 2020 09:49

UK BROKER RATINGS SUMMARY: BHP Gets Upgrades From JPMorgan, Deutsche

UK BROKER RATINGS SUMMARY: BHP Gets Upgrades From JPMorgan, Deutsche

Read more
18 Mar 2020 13:42

Wednesday broker round-up

(Sharecast News) - Polypipe: Deutsche Bank upgrades to buy with a target price of 550p.

Read more
12 Mar 2020 16:05

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
11 Mar 2020 13:37

Wednesday broker round-up

(Sharecast News) - Clinigen Group: Liberum upgrades to buy with a target price of 780.0p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.